Zydus Lifesciences gets USFDA nod for Rifaximin tablets

Rifaximin tablets are indicated for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults. The tablets will be produced at the Group's manufacturing facility at SEZ II, Ahmedabad.

According to IQVIA MAT 2025, Rifaximin tablets had annual sales of USD $2,672.9 million in the United States.

The group now has 427 approvals and has filed 492 Abbreviated New Drug Applications (ANDAs) since the commencement of the filing process in FY 2003-04.

The company's consolidated net profit shed 0.96% to Rs 1,170.9 crore on 17.21% rise in revenue from operations to Rs 6290.2 crore in Q4 FY25 over Q4 FY24.

Zydus Lifesciences is a discovery-driven, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.

Shares of Zydus Lifesciences shed 0.53% to Rs 924.95 on the BSE.

Powered by Capital Market - Live News